论文部分内容阅读
Objective: To evaluate the safety and pharmacokinetics of the intropritoneal(IP) drinistra tion of the antineoplastic agent taxol. Methods: Eight pretreated patients with advanced ovarian cancer entered into a trial and were treated with taxol administrated IP in 3L of normal saline every 3 weeks. The dose was 175mg/m2 .Results:The toxicity was severe pain and severe leukopenia. The exposure of the peritoneal cavity (peak levels and area under the time - versus - concentration) to taxol after IP admimistration more than the plasma 400 fold significant concentration of taxol persisted within the peritoneal cavity for more than 24 hours af ter a single IP administration. Conchusion: Taxol can be delivered by the IP route with both an acceptable toxicity profile and major pharmacokinetic advantage for cavity exposure.
Objective: To evaluate the safety and pharmacokinetics of the intropritoneal (IP) drinistra tion of the antineoplastic agent taxol. Methods: Eight pretreated patients with advanced ovarian cancer entered into a trial and were treated with taxol administered IP in 3L of normal saline every 3 weeks The dose was 175 mg / m2. Results: The toxicity was severe pain and severe leukopenia. The exposure of the peritoneal cavity (peak levels and area under the time - versus - concentration) to taxol after IP admimistration more than the plasma 400 fold significant concentration of taxol persisted within the peritoneal cavity for more than 24 hours af ter a single IP administration. Conchusion: Taxol can be delivered by the IP route with both acceptable sensitivity profile and major pharmacokinetic advantage for cavity exposure.